Conflict of interest:
GC receives fees from Bayer and Elea-Phoenix (Argentina) and
participates on the data safety monitoring board or advisory board for
Bayer (Larotrectinib).
SLF receives personal fees from Riverboat Study (Research into Visual
endpoints and Rb
Health outcomes - 5R01CA225005-03- Salary support), WHO NCD Childhood
Cancer – consultant (salary support)-, St Jude Global consultant, St
Jude Children’s Research Hospital, Memphis TN, USA, Global
Retinoblastoma studies (salary Support).
SLF is also a SLAOP Board member and works at the Retinoblastoma
Advisory committee, St Jude Global Alliance, St Jude Children’s Research
Hospital.
All other authors declare no competing interests.
Role of funding source : No funding was used for this study
Ethics committee approval: All responses were anonymous and
institutional ethical review was not required.